Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 815 for:    IBUPROFEN

Clinical Pharmacogenetic of Ibuprofen After Lower Third Molar Surgeries

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03169127
Recruitment Status : Active, not recruiting
First Posted : May 30, 2017
Last Update Posted : July 12, 2019
Sponsor:
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Information provided by (Responsible Party):
Giovana Maria Weckwerth, University of Sao Paulo

Brief Summary:
The present clinical trial randomized will be to assess the link between the different haplotypes of CYP2C8 and CYP2C9 genes and the clinical efficacy of ibuprofen after lower third molar extractions. Onset, duration of postoperative analgesia, duration of anesthetic action on soft tissues, intraoperative bleeding, hemodynamic parameters, postoperative mouth opening and wound healing at the 7th postoperative day were evaluated. For this purpose, 200 healthy volunteers underwent removal of one lower third molar, under local anesthesia with articaine 4% (1:200,000 adrenaline) will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.

Condition or disease Intervention/treatment Phase
Pain Other Surgical Procedures Impacted Third Molar Tooth Drug: Ibuprofen 600 mg Phase 4

Detailed Description:

The aim of this study will be to assess the link between the different haplotypes of CYP2C8 and CYP2C9 genes and the clinical efficacy of ibuprofen after lower third molar extractions regarding pain, swelling and trismus, adverse reactions, the amount of pain medication used, the patient satisfaction with the drug and the influence of the ability on preoperative modulation of conditioned pain. We will evaluate also the relationship between the different haplotypes of OPRM1 gene (SNP A118G), the salivary concentrations of pro-inflammatory cytokines (IL-2, IL-4, IL-6, IL-10 and TNF-±), and preoperative conditioned pain modulation. Therefore, 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.

For analysis of the proposed genes, saliva will be collected, which will serve as a source of genomic DNA. For molecular analysis it will be performed polymerase chain reaction (PCR). All tests will be conducted and validated by Applied Biosystems®. Also it will be held in the research, genetic sequencing of the genes CYP2C8, CYP2C9 and OPRM1, to verify possible correlations of these genes with postoperative pain and pain modulation.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Clinical Pharmacogenetic of Ibuprofen Enantiomers After Lower Third Molar Surgeries
Actual Study Start Date : April 1, 2016
Actual Primary Completion Date : July 30, 2018
Estimated Study Completion Date : July 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental Group Ibuprofen 600mg
Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
Drug: Ibuprofen 600 mg
After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
Other Name: Lower third molar surgery with ibuprofen for pharmacogenetic




Primary Outcome Measures :
  1. Evaluation of changes in the postsurgical pain during the first 24 hours until 96 hours after the procedure [ Time Frame: Seventh postoperative day ]
    Subjective evaluation of postsurgical pain, which was annotated by the volunteer after the surgery, in a Visual Analogue Scale (VAS, 0-100 mm). The subjective pain evaluations will be performed by patients at the following times after administration of the drug [0, 15, 30 and 45 min, 1; 1.5; 2; 3; 4; 5; 6; 7; 8; 10; 12; 16; 24 hr, 48, 72 and 96 h]. What will be taken into account on this outcome is the representation of the postsurgical pain, that will be noted on the Visual Analogue Scale (in millimeters) in respective moments.

  2. Quality of anesthesia [ Time Frame: During the surgical procedure ]
    Quality of anesthesia during surgery based on a category 3point scale: 1) the patient reported no discomfort; 2) the patient reported discomfort, without the need to supplement the anesthesia; 3) reported some discomfort by the patient, requiring anesthesia complementation. Intraoral bleeding that will be evaluated by the surgeon according to a 3point scale (1: minimal, 2: normal and 3: Maximum), immediately after the following steps: injection of the first cartridge anesthesia, incision, mucoperiosteal detachment, osteotomies, tooth section, extraction, cleaning and suturing.

  3. Intraoperative bleeding during the surgeries steps [ Time Frame: During the surgical procedure ]
    Intraoperative bleeding, rated by the surgeon according to a 3 point category rating scale (1 minimal bleeding; 2 normal bleeding; 3 excessive bleeding) (SISK, 1986), immediately after the following steps: injection of the first cartridge of articaine, tissue incision, flap reflection, bone removal (when this procedure was necessary), tooth extraction, cleaning of the operated site, and completion of suturing.

  4. Blood pressure variability during the surgeries steps [ Time Frame: During the surgical procedure ]
    Systolic blood pressure, diastolic, and mean to be verified and recorded at surgical moments previously described (injection of the first cartridge anesthesia, incision, mucoperiosteal detachment, osteotomies, tooth section, extraction, cleaning and suturing), carried out with the aid of a system for monitoring hemodynamic parameters.

  5. Heart rate variability during the surgeries steps [ Time Frame: During the surgical procedure ]
    Heart rate to be verified and recorded surgical at moments described above, carried out with the aid of a system for monitoring hemodynamic parameters.

  6. Oxygen saturation variability during the surgeries steps [ Time Frame: During the surgical procedure ]
    Oxygen saturation to be verified and recorded at surgical moments described above, carried out with the aid of a system for monitoring hemodynamic parameters.

  7. Subjective evaluation of postsurgical pain at the moment of the rescue medication utilization [ Time Frame: Seventh postoperative day ]
    Subjective evaluation of postsurgical pain at the moment of the rescue medication consumption which was annotated by the volunteer after the surgery, in a Visual Analogue Scale (VAS, 0-100 mm).


Secondary Outcome Measures :
  1. Postoperative mouth opening [ Time Frame: Second and Seventh postoperative days ]
    Mouth opening (mm) between the mesial-incisal corners of the upper and lower right central incisors at maximum opening of the jaws was measured and recorded before the surgery and during the second and seventh postoperative days.

  2. Onset and duration of surgery after administration of local anesthetic [ Time Frame: During the surgery ]
    Will only be considered those surgeries in which there is no difference in the duration time of the procedure between the patients. This time count will be started after the administration of the first local anesthetic. Unit of mesure used will be hours.

  3. Incidence, type and severity of adverse reactions after the surgery [ Time Frame: Seventh postoperative day ]
    Will be considered as adverse reactions: gastrointestinal irritation, nausea, vomiting, bleeding, allergy, headache, dizziness, drowsiness or any other type of reaction presented after surgery.

  4. Total amount of rescue medication [ Time Frame: Seventh postoperative day ]
    The total amount of rescue medication that was used by the patient during the postoperative period (Acetominophen- 750 mg) will be analyzed.

  5. Measurement the facial edema [ Time Frame: On the second day after surgery and on the seventh day after surgery. ]
    It will apply the method used by Ustun et al. (2003), which takes into account the sum of the following measures (obtained with flexible tape measure): A) distance between the lateral corner of the eye and the gonion, B) away from the tragus corner of the mouth and C) away from the tragus to the soft tissue of pogonion. Preoperative sum of three measures will be considered as the baseline that way. The difference between the values obtained in the postoperative period and baseline indicate the facial edema in the 2nd and 7th days.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Need of lower third molar surgeries

Exclusion Criteria:

  • Presence of systemic diseases;
  • Presence of local inflammation and/or infection;
  • Any history of allergic reaction to local anesthetics, gastrointestinal bleeding or ulceration;
  • Cardiovascular, kidney or hepatic diseases;
  • Patients who are making use of antidepressants, diuretics or anticoagulants;
  • Asthma and allergy to aspirin, ibuprofen or any other nonsteroidal antiinflammatory drug;
  • Regular use of any nonsteroidal antiinflammatory drug,
  • Pregnancy or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03169127


Locations
Layout table for location information
Brazil
University of São Paulo
Bauru, SP, Brazil, 17017-901
Sponsors and Collaborators
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
Investigators
Layout table for investigator information
Principal Investigator: Giovana M Weckwerth, DDS 416.016.638-54

Layout table for additonal information
Responsible Party: Giovana Maria Weckwerth, DDS, PhD student, Principal Investigator, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT03169127     History of Changes
Other Study ID Numbers: 59807716.9.0000.5417
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Giovana Maria Weckwerth, University of Sao Paulo:
Ibuprofen
Lower third molar
Oral Surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Ibuprofen
Tooth, Impacted
Tooth Diseases
Stomatognathic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action